- In January 2025, the U.S. FDA approved Amgen’s combination therapy of Lumakras and Vectibix for treating metastatic colorectal cancer with specific gene mutations. This approval was based on a late-stage study showing increased progression-free survival
- In October 2024, the adoption of robotic-assisted surgeries, such as those using the da Vinci Surgical System, has increased, offering benefits such as shorter recovery periods and enhanced precision in colorectal procedures. Studies have highlighted superior outcomes with robotic surgery compared to traditional methods
- In September 2024, Olympus Corporation received FDA 510(k) clearance for its CADDIE system, an AI-powered tool designed to assist gastroenterologists in detecting colorectal polyps during colonoscopy procedures, enhancing diagnostic accuracy
- In May 2024, The U.S. Preventive Services Task Force recommended lowering the starting age for colorectal cancer screening to 45. This policy change is expected to increase demand for diagnostic and surgical procedures, driving market growth
- In April 2024, Researchers from the UK developed a tiny, magnetically guided robot aimed at detecting and treating bowel cancer. This 3D-printed device, the size of a UK penny, has shown promise in early trials and could streamline cancer screening and treatment processes
